Teflaro's Key Patent Expiration
Ceftobiprole medocaril sodium (Teflaro), developed by Basilea Pharmaceutica and licensed to Allergan (acquired by AbbVie in 2020), has its primary U.S. composition of matter patent (US 6,653,300) expiring in 2026.[1][2]
When Does Teflaro's Exclusivity End?
Pediatric exclusivity extends market protection to May 2027, delaying generic entry. No new drug application (NDA) exclusivity remains active.[1][2]
AbbVie's Role and Licensing Details
AbbVie markets Teflaro in the U.S. under license from Basilea. Basilea holds the patents; AbbVie has no independent patents listed for it in the FDA Orange Book.[2]
Will Generics Launch in 2027?
Two ANDA filings from MSN Laboratories challenge the '300 patent, with final court decisions pending. If invalidated, generics could enter before 2027.[1][2]
Global Patent Status
In Europe, key patents expired in 2021, allowing generic ceftobiprole entry. Japan patents run through 2029.[2]
[1]: FDA Orange Book
[2]: DrugPatentWatch.com - Teflaro